Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.34B.
ENTERPRISE VALUE (EV)
$2.34B
Supernus Pharmaceuticals, Inc.
Market Cap
$2.47B
Enterprise Value (EV)
$2.34B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.47B | $2.34B |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | $1.92B |
| Clover Health Investments, Corp. (CLOV)vs › | $2.39B | $2.19B |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.57B | $2.15B |
| Disc Medicine, Inc. (IRON)vs › | $2.36B | $2.33B |
| Beam Therapeutics Inc. (BEAM)vs › | $2.58B | $2.61B |
| Neogen Corporation (NEOG)vs › | $2.59B | $3.20B |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | $2.41B |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | $2.33B |
Market Cap
$2.47B
Total Debt
$0.00
Cash
$128.45M
Enterprise Value
$2.34B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
